Paul Cleveland Joins Mohr Davidow

Early stage venture firm Mohr Davidow has added Paul Cleveland as a general partner and as chief operating officer. Cleveland joins from Affymax, a pharmaceutical company, where he was chief financial officer and executive vice president of corporate development. In his new role, Cleveland will be responsible for all finance, operations and administrative functions at Mohr Davidow, the firm said in a statement.

PRESS RELEASE

Mohr Davidow, a leading early stage Silicon Valley venture capital firm, today announced the appointment of Paul Cleveland. He joins the firm both as a General Partner and in the newly created position of Chief Operating Officer, where he will be responsible for all finance, operations and administrative functions of the firm.

“The Mohr Davidow team is clearly passionate about entrepreneurship and innovation,” Cleveland said. “The firm’s strength lies in its multi-disciplinary approach, which you can see reflected in the startups they invest in and work with. I look forward to being part of a team focused on solving fundamentally difficult problems, and creating significant value across Cleantech, IT and Life Sciences.”

Cleveland joins Mohr Davidow from Affymax, a pharmaceutical company, where he was chief financial officer and executive vice president of corporate development. Prior to that he was a managing director at Integrated Finance, Ltd., an investment bank, where he advised large international corporations on financial and mergers and acquisitions strategy. Previously, he was managing director and head of West Coast mergers & acquisitions for JPMorgan (formerly Hambrecht & Quist). While there, he was responsible for more than 50 completed transactions involving healthcare and technology companies ranging in size from $100 million to more than $20 billion.

Earlier in his career, Cleveland was a corporate lawyer at Cooley Godward in Palo Alto, Calif., and Sidley & Austin and Davis Polk & Wardwell in New York. He has lectured widely on the topics of mergers and acquisitions, securities laws, and the duties of directors of public companies. He earned his J.D. from Northwestern University School of Law in Chicago and his A.B. from Washington University in St. Louis. Cleveland currently serves on the boards of Sangamo Biosciences and Grace Cathedral, the Episcopal cathedral of San Francisco.

“I’ve known Paul for many years,” added Mohr Davidow Managing Partner Bill Ericson. “It was clear from our early days together that Paul was a natural leader, a strategic thinker and someone driven to achieve top results. His career demonstrates those qualities and more. He will be a superb addition to our team.”

About Mohr Davidow
For more than 25 years, the Mohr Davidow team has invested in early stage startups and worked closely with exceptional entrepreneurs to move innovation forward, and to develop and deliver new, technology-based ideas, products and services. The firm invests in companies that transform industries whether through better infrastructure for our rapidly evolving data-intensive digital world, more efficient power for our planet, or better, more personalized medicine. Category-leading companies funded by Mohr Davidow include: Agile (ORCL); AudienceScience; Brocade (BRDC); Genomatica; GridIron Systems; Nanosolar; nLight; ONI Systems (CIEN); Rally Software; Recurrent Energy (acquired by Sharp Corporation); Pacific Biosciences (PACB); Panasas; ParAllele (AFFX); ParAccel; Proofpoint; OPXBIO; RainDance Technologies; Rally Software; Rambus (RMBS); Shutterfly (SFLY); Simbol Materials; Ticketfly; Visible Measures; and ZeaChem. The firm has $1.85 billion under management.